Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma

Abstract

BackgroundThe purpose of this study was to evaluate the effects of benzalkonium (BAK)-free travoprost monotherapy administered for 3 years on intraocular pressure and visual field performance.MethodsThe intraocular pressure of 76 patients with normal tension glaucoma was monitored every 1–3 months. A Humphrey visual field test was performed every 6 months after treatment and compared with the results before treatment. Visual field performance was also evaluated by trend and event analysis.ResultsThirty cases discontinued within 3 years. Mean intraocular pressure after 3 years of travoprost treatment (14.1 ± 2.4 mmHg) was significantly lower than that before treatment (16.8 ± 2.6 mmHg, P < 0.0001). There was no change in the mean deviation and pattern standard deviation as measured by Humphrey visual field test after 3 years of treatment compared with before treatment. Visual field performance was worse in one patient (2.8%) by trend analysis and five patients (13.9%) by event analysis. Treatment was discontinued in six cases (7.9%) due to the appearance of adverse reactions.ConclusionBAK-free travoprost monotherapy was effective in reducing intraocular pressure for at least 3 years; however, visual field performance worsened in 2.8%–13.9% of patients with normal tension glaucoma.

Travoprost with sofZia&reg; preservative system lowered intraocular pressure of Japanese normal tension glaucoma with minimal side effects

“…Travoprost with sofZia® use has been reported in limited numbers of NTG patients, with a potent IOP lowering effect and minimal corneal damage. 12 , 13 We, therefore, expanded on these findings and conducted a study with a large number of Japanese NTG patients.…”

The diurnal and nocturnal effects of travoprost in&nbsp;normal-tension glaucoma

“…In 2009, Suh et al reported an 18.8%–25.1% IOP reduction with travoprost in 45 patients with unilateral NTG after 12 months of treatment 8. In the longest-term follow-up, Inoue et al recently reported a 16% IOP reduction with travoprost in NTG patients at 3 years 7. In a randomized controlled trial, Ang et al analyzed the effect of travoprost on diurnal IOP (8 am to 5 pm) in 54 NTG patients 9.…”

“… 8 In the longest-term follow-up, Inoue et al recently reported a 16% IOP reduction with travoprost in NTG patients at 3 years. 7 In a randomized controlled trial, Ang et al analyzed the effect of travoprost on diurnal IOP (8 am to 5 pm) in 54 NTG patients. 9 At 6 months, the average diurnal IOP was significantly reduced by 16.1%, with only 32.9% achieving an IOP reduction >20%.…”

“…We have previously reported significant IOP reductions during treatment with travoprost with sofZia ® (Travatan Z ® [TZ]; Alcon Laboratories, Inc.) throughout a 24-hour period in patients with OHTN or OAG 6. The efficacy of travoprost in an NTG population has been less robust, with IOP reductions ranging from 16.1%–25.1% based on a relative paucity of data 7–9. The IOP-lowering effects of travoprost throughout the 24-hour cycle in NTG patients is poorly characterized, and monitoring these effects in the habitual position has not been reported previously.…”

Comparison of Cytotoxic Effects on Rabbit Corneal Endothelium between Preservative-free and Preservative-containing Dorzolamide/timolol

“…The adverse effects associated with these preservatives seem to be more significant for glaucoma patients, mainly because of their chronic use of one or more preservative-containing agents [ 6 ]. Therefore, considerable efforts have been made in the recent years by pharmaceutical companies to develop less toxic glaucoma medications such as preservative-free preparations [ 7 ].…”